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Abstract
Background: Heart failure (HF) is strongly associated with aging. It affects 10–12% of
patients older than 80 years, with five-year overall mortality after first hospitalization for HF
being as high as 81%. The main objective of this study was to assess the diagnosis and
treatment of HF in hospitalized octogenarians compared to younger subjects.
Methods: The survey was performed among a random sample of all Polish hospitals and in
all academic centers, as part of the National Project of Prevention and Treatment of Cardio-
vascular Diseases in Poland — POLKARD. Using a questionnaire-based method, hospital
documentation of the last five patients with diagnosed HF was reviewed. Eventually, in 2005,
HF patients of 259 internal medicine and cardiology hospital wards, including 260 very
elderly patients, were selected to the study.
Results: The mean age of the 1,289 studied patients was 69.8 ± 11.4 years (age range: 26–96
years), 57.8% were males, and 80.1% were in NYHA class III or IV. Echocardiography was
performed in 41.7% of octogenarians in comparison with 58.7% of those categorized as
‘younger elderly’, i.e. 60–79 years, and 75.2% of patients aged below 60 years (p < 0.0001).
The most prescribed drugs in very elderly patients were diuretics (86.9%, p = 0.005) and
ACE-I (81.9%), while only 61.5% used beta-blockers (p < 0.0001). In stepwise logistic regres-
sion analysis, hypertension, history of myocardial infarction and admission to cardiology
ward were positively associated with beta-blocker and ACE-I (or ARB) therapy, while older age
and pulmonary diseases (COPD or asthma) were related to their non-prescription.
Conclusions: Despite significant progress in HF management, there is still a need for an
improvement in the medical care of very elderly patients. The major obstacles seem to be
advanced age and the presence of coexistent pulmonary diseases. Therefore, the participation of
geriatricians and pulmonologists should be recommended in caring for octogenarians with HF.
(Cardiol J 2012; 19, 2: 146–152)
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Introduction
Heart failure (HF) affects approximately 5% of
the adult population of Western Europe [1]. Due to
improved outcomes in cardiovascular diseases and
prolonged lifespans, HF represents an increasing
problem for public healthcare , and is now the com-
monest diagnosis in the population of patients aged
over 65 who have been discharged from hospital [2].
HF is strongly associated with aging. It affects 10–
–12% of patients older than 80 years, with five-year
overall mortality after first hospitalization for HF
being as high as 81% [3, 4].
The international research project the Euro
Heart Failure Survey (EHFS) [5, 6], which was also
performed in Poland, revealed a gap between the
hospital care of patients with HF and the European
Society of Cardiology (ESC) guidelines [7]. This
project focused on European patients hospitalized
for HF, and showed age-related suboptimal manage-
ment regarding both diagnostic procedures and
pharmacotherapy [8, 9]. However, centers invited
to participate in this and similar HF surveys were
largely based on university hospitals [5, 6, 10, 11],
so the data only partially represented general hos-
pital practice.
The present study was performed as part of the
National Project of Prevention and Treatment of
Cardiovascular Diseases — POLKARD [12]. The
aim of the presented analysis was to assess HF dia-
gnosis and treatment in Polish hospitals in very
elderly patients (over 80 years old) in comparison
with younger elderly (60–79 years old) and patients
under 60 years of age.
Methods
The multi-stage procedure of choosing hospi-
tals to be investigated, which was designed to ob-
tain a representative sample of both medical wards
and HF patients discharged from hospitals, has been
previously published in detail [12, 13]. Stratified
multistage sampling of hospitals was based on the
governmental registration list (posted on 17 March
2005). A total of 260 hospitals (of which one refused
to take part in the research) with internal medicine
and cardiology departments were approached. All
Polish university hospitals were asked to partici-
pate in the study. The percentage of patients treat-
ed at university hospitals in the present analysis
was 10.1%. Consequently, from 21 April to 31 De-
cember 2005, the medical records of the last five
patients discharged with a diagnosis of HF were
analyzed.
Data was obtained from HF patients’ medical
files concerning their medical history, diagnostic
and therapeutic procedures by specially trained
nurses.
In total, 1,289 patients who had been dis-
charged alive from hospital with an HF diagnosis
were enrolled into the analysis; 20.2% of these pa-
tients were at least 80 years old. Active neoplastic
disease was the only exclusion criterion. All proce-
dures of data gathering were subject to Polish re-
gulations.
Statistical analysis
The study population is described by percent-
ages and absolute numbers. The distribution of con-
tinuous variables is characterized by means and
standard deviations. Categorical variables were
compared between subgroups by c2 test and con-
tinuous variables by analysis of variance (ANOVA
test). Age was analyzed as a continuous and cate-
gorical variable (< 60, 60–79 and ≥ 80 years). Two-
-sided p value tests were performed.
Determinants for the use of beta-blockers,
spironolactone and a combination of beta-blocker
with angiotensin-converting enzyme inhibitor
(ACE-I) or angiotensin II receptor blocker (ARB)
medication were analyzed by stepwise multiple logis-
tic regression. Clinical characteristics: age, gender,
New York Heart Association (NYHA) class, HF with
preserved ejection fraction (HFPEF), HF type, admis-
sion ward, intensive care unit (ICU) stay, and co-mor-
bidities: hypertension, ischemic heart disease, atrial
fibrillation (AF), chronic obstructive pulmonary dis-
ease (COPD) or asthma, renal dysfunction, prior
stroke or transient ischemic attack (TIA), myocardial
infarction (MI) or invasive cardiology treatment were
considered for inclusion in the models.
The multiple logistic regression variables
choice was based on a significance level of p < 0.1
in the univariate comparison; a p value < 0.05 was
set up for variables entered into the closing model.
Finally, gender, age, hypertension, COPD or asth-
ma, MI, renal insufficiency, HFPEF and admission
to cardiology ward gained statistical significance and
were involved.
A significance level of 0.05 was assumed for
statistical tests. Statistical analyses were complet-
ed with Statistica 8.0 PL (StatSoft, Poland).
Results
Patients’ characteristics
Mean age of the 1,289 patients was 69.8 ± 11.4
(age range: 26–96) years. Most of them were males
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(57.8%), and 80.1% presented HF in NYHA class III
or IV (Table 1). Most of the NYHA class I cases
were diagnosed in patients under 60 years old, while
NYHA classes III–IV were diagnosed most fre-
quently in patients over 80 years of age.
Coronary artery disease, hypertension and AF
were more frequently observed in very elderly par-
ticipants compared to patients between 60 and
79 years and subjects under the age of 60. Co-mor-
bidities including stroke/TIA, anemia, COPD or asth-
ma and renal failure were more common in octoge-
narians, whereas liver disease and obesity were more
often found in the youngest investigated group. De-
tails of patients’ characteristics are shown in Table 1.
Almost 76% of patients over 80 years and 71%
of persons aged 60–79 were treated at internal
medicine wards; younger patients were treated
more frequently in cardiology departments (51%,
p < 0.0001). Of all HF patients, 32.7% were admit-
ted to ICU, with a similar length of stay in all age
groups (4.7 ± 4.6 days).
Diagnostics
Only 41.7% of very elderly patients in compar-
ison with younger patients underwent echocardio-
graphy during the surveyed hospitalization (p <
< 0.0001; Table 2). B-type natriuretic peptide
(BNP) was measured in only 1.2% of very elderly
patients and in 8.4% of persons in the youngest
group. The commonest reason (in about 60% of
cases) for not estimating BNP levels in all age
groups was the low availability of this test.
Coronarography, 24-h ECG and exercise test
were significantly less frequently performed in oc-
togenarians. An analogous tendency was observed
for spirometry, while chest radiogram was more
often made in the oldest age group (Table 2).
Pharmacological treatment
As we have published elsewhere [13], the most
frequently used medication in all HF patients were
diuretics (86.8%; Table 3). ACE-I and ARBs were
used with similar frequency in all compared age-
groups. Beta-blockers, spironolactone, as well as
a combination of beta-blockers and ACE-I (or ARB)
were less commonly prescribed in patients ≥ 80 ye-
ars old compared to both younger age groups.
Antiplatelet therapy was more commonly used in
octogenarians (p < 0.03). Statins were more likely
to be prescribed in younger patients, compared to
patients aged 60–79 or octogenarians, respectively
45.8%, 38.7% and 26.9%; p < 0.001 (Table 3).
Table 1. Characteristics of the study population (n = 1,289) divided by age group.
Age ≥ 80  (n = 260) Age 60–79  (n = 754) Age < 60  (n = 275) P
Male gender 41.6% (106/255) 55.1% (405/735) 80.4% (217/270) < 0.0001
Age (years) 84.0 ± 3.5 71.1 ± 5.3 52.8 ± 6.2 < 0.0001
NYHA class:
I 0.0% (0/256) 0.5% (4/746) 1.8% (5/273)
II 15.6% (40/256) 19.8% (148/746) 20.9% (57/273) 0.082
III 53.9% (138/256) 51.9% (387/746) 47.3% (129/273)
IV 30.5% (78/256) 27.8% (207/746) 30.0% (82/273)
Cardiovascular diseases:
Hypertension 78.1% (203/260) 74.7% (553/740) 58.1% (158/272) < 0.0001
CAD 78.4% (196/250) 75.6% (551/729) 64.9% (172/265) < 0.001
Myocardial infarction 30.9% (77/249) 38.1% (276/724) 40.0% (104/260) 0.070
Atrial fibrillation 49.6% (126/254) 47.2% (349/740) 28.8% (76/264) < 0.0001
Co-morbidities:
Diabetes 29.8% (76/255) 36.7% (274/746) 27.4% (74/270) 0.008
TIA or stroke 14.6% (36/246) 12.6% (93/736) 7.8% (21/268) 0.043
Anemia 16.8% (43/256) 10.7% (79/742) 8.7% (23/265) 0.008
COPD or asthma 25.3% (64/253) 20.0% (148/740) 14.7% (39/266) 0.010
Renal failure 28.4% (72/254) 19.6% (145/740) 10.8% (29/268) < 0.0001
Liver disease 4.8% (12/248) 10.8% (78/722) 19.5% (51/261) < 0.0001
Obesity 21.9% (55/251) 37.2% (273/734) 37.9% (102/269) < 0.0001
Numbers in brackets indicate: frequency/available data; NYHA — New York Heart Association; CAD — coronary artery disease; TIA — transient
ischemic attack; COPD — chronic obstructive pulmonary disease
149
Paweł Matusik et al., Age-related gap in HF management
www.cardiologyjournal.org
Previous MI was positively associated with
beta-blockers prescription (OR = 1.89; 95% CI 1.40–
–2.55), whereas age (OR = 0.98; 95% CI 0.96–0.99)
and a history of respiratory disease (OR = 0.43; 95%
CI 0.31–0.59) were related to their non-prescrip-
tion (all data is significant at p < 0.001).
The combination of beta-blockers and ACE-I
(or ARBs), hypertension, history of MI, and admis-
sion to cardiology department were positively re-
lated to their prescription, while increased age and
presence of asthma or COPD were predictors of
non-prescription (Fig. 1).
Older age, male gender, the presence of hyper-
tension, renal failure, and HFPEF were associated
with non-spironolactone therapy (Fig. 2).
Invasive procedures
We found that 26.5% of patients in the young-
est group vs 18.7% of subjects 60–79 years of age
and 6.0% of octogenarians (p < 0.0001) had under-
gone interventional cardiology procedures or car-
diac surgery during their last hospitalization or in
the past (17.8% of all investigated HF patients).
The commonest cardiac surgery procedure in
the group of very elderly patients was pacemaker
implantation (10.4%); this procedure was performed
respectively in 11.2% and 1.8% of patients aged 60–
–79 and < 60 years (p < 0.001). Marked differenc-
es between HF octogenarians, younger elderly pa-
tients (60–79 years old) and patients < 60 years of
age were observed in prevalence of balloon angio-
plasty (respectively: 4.6% vs 12.5% vs 23.8%, p <
< 0.0001), stent implantation (3.8% vs 14.1% vs
25.0%, p < 0.0001), coronary artery bypass grafting
(1.5% vs 9.1% vs 10.7%, p = 0.008) and valvular pro-
cedures (0.0% vs 3.6% vs 6.5%, p = 0.011).
There were no significant differences between
age-category groups in cardiac resynchronization
therapy (performed in eight patients), implantation
of cardioverter-defibrillator (18 patients) or heart
transplantation (two patients).
Discussion
We analyzed a population of hospitalized HF
patients divided into three age categories. Octoge-
Table 3. Heart failure pharmacotherapy during hospitalization.
Age ≥ 80  (n = 260) Age 60–79  (n = 754) Age < 60  (n = 275) P
ACE-I 81.9% (213/260) 84.2% (635/754) 82.6% (227/275) 0.632
ARB 1.2% (3/260) 2.1% (16/754) 2.2% (6/275) 0.588
Beta-blocker 61.5% (160/260) 74.5% (562/754) 83.3% (229/275) < 0.0001
Combination of ACE-I 52.7% (137/260) 65.8% (496/754) 72.4% (199/275) < 0.0001
or ARB and beta-blocker
Diuretics (except for 86.9% (226/260) 88.9% (670/754) 81.1% (223/275) 0.005
spironolactone)
Spironolactone 56.9% (148/260) 61.5% (464/754) 71.6% (197/275) 0.001
Digitalis 41.2% (107/260) 38.6% (291/754) 33.5% (92/275) 0.164
Antiplatelet treatment 72.7% (189/260) 63.7% (480/754) 66.6% (183/275) 0.029
Numbers in brackets indicate: frequency/available data; ACE-I — angiotensin-converting enzyme inhibitor; ARB — angiotensin II receptor blocker
Table 2. Procedures performed in heart failure patients during surveyed hospitalization.
Age ≥ 80  (n = 260) Age 60–79  (n = 754) Age < 60  (n = 275) P
BNP/NT-proBNP 1.2% (3/241) 2.5% (18/709) 8.4% (22/263) < 0.001
Urine test 91.9% (239/260) 91.7% (685/747) 84.6% (230/272) 0.001
Chest X-ray 82.6% (213/258) 79.9% (591/740) 72.1% (196/272) 0.007
Echocardiography 41.7% (108/259) 58.7% (442/753) 75.2% (206/274) < 0.0001
Coronarography 1.9% (5/260) 4.7% (35/752) 16.4% (45/275) < 0.0001
Spirometry 4.1% (10/247) 6.4% (45/705) 9.3% (24/258) 0.056
24-h ECG 9.7% (24/247) 17.4% (123/708) 25.7% (67/261) < 0.0001
Exercise test 0.4% (1/245) 5.9% (41/700) 12.8% (33/258) < 0.0001
Numbers in brackets indicate: frequency/available data; BNP — B-type natriuretic peptide; NT-proBNP — N-terminal pro-BNP; ECG — electrocardiography
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narians were more frequently women, with more
cardiovascular diseases (hypertension, coronary
artery disease, AF) and higher presence of co-mor-
bidities (stroke/TIA, anemia, COPD/asthma, renal
failure), while liver insufficiency and obesity were
more common in younger patients. In the studied
group of very elderly patients when compared to
previous European surveys [8, 9], we observed
a similar predominance of women, occurrence of AF,
and diabetes, while coronary artery disease and
hypertension were more prevalent.
Only 10% of the patients included in our study
were treated in university hospitals. Most other
significant studies of HF patients have recruited
significantly more from university hospitals. The
figures are: in Euro Heart Failure Survey (EHFS) I
and II, Acute Decompensated Heart Failure Na-
tional Registry (ADHERE) and Organized Program
to Initiate Lifesaving Treatment in Hospitalized
Patients with Heart Failure (OPTIMIZE-HF):
50%, 47%, over 30% and over 56%, respectively
[6, 10, 11, 14]. This may partly explain some
differences in HF management between studies,
suggesting more optimal management in academic
centers.
The presented POLKARD study demonstrates
an underuse of recommended HF diagnostic pro-
cedures in octogenarians. Coronarography was per-
formed in only 1.9% of octogenarians and in 17% of
very elderly patients in the EHFS II. An optimistic
tendency observed in EHFS II of a doubling in-
echocardiography assessment in octogenarians
when compared to EHFS I (from 38.4% to 81.0%)
was not confirmed in our analysis (only 41.7% of
patients with left ventricular ejection fraction
record). Taking into account the results of the study
of Lien et al. [15] concerning HF in frail elderly pa-
tients of median age 86 years, which showed that
the specificities of clinical signs, chest X-rays and
abnormal ECGs for HF were low (respectively:
50%, 20% and 9%), it seems that a diagnosis based
on symptoms and X-ray might be misleading in eld-
erly HF patients. Since the EHFS I was conducted,
prescribing rates for beta-blockers, ACE-I/ARB and
their combination in discharged alive octogenarians
has increased when compared with the POLKARD
Study (beta-blockers from 25% to 61.5%; ACE-I/
/ARB from 56% to 82.7% and a combination of beta-
-blocker and ACE-I/ARB from 15% to 52.7%), with
an only slightly lower percentage of patients with
respiratory disease (EHFS I: 32.2%; POLKARD:
25.3%). Similarly to the Worcester Heart Failure
Study, [11] we found that older patients were less
likely to be prescribed lipid-lowering agents.
Very few previously published studies compar-
ing the clinical features in HF management between
different age groups, have reported invasive cardio-
logy procedures. Poor prognosis [4] in HF and the
high costs [2] of certain invasive cardiology proce-
dures may explain some differences in their perfor-
mance between age groups. We have found that
10.4% of very elderly patients were treated with
pacemaker implantation, which indicates no signifi-
cant difference to prior European investigation
(10.1% of octogenarians in EHFS I) [8].
Figure 2. Determinants of spironolactone therapy in heart
failure patients; EF — ejection fraction; OR — odds
ratio; CI — confidence interval; all data is significant at
p < 0.05.
Figure 1. Determinants of combined therapy of angio-
tensin-converting enzyme inhibitor (ACE-I) or angioten-
sin II receptor blocker (ARB) and beta-blocker in heart
failure patients; COPD — chronic obstructive pulmona-
ry disease; OR — odds ratio; CI — confidence interval;
all data except for gender is significant at p < 0.05.
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Our obtained results show differences in char-
acteristics, diagnostic procedures, pharmacological
and invasive treatment of octogenarians compared
to younger HF patients. These findings are consis-
tent with previously published large epidemiologi-
cal studies [8, 9, 16–19].
The results of our study must be interpreted
within context of its potential limitations. In the
present study, we did not assess hospital stays
which concluded in the patient’s death, and data was
collected retrospectively based on medical records.
Also, the data was gathered six years ago.
Possible causes of age-related gap
in heart failure management
Hospital management of the very elderly with
HF may often be suboptimal, compared to guide-
lines, because of the specificity of geriatrics. The
difficulties of managing elderly patients are associ-
ated with the very prevalent and increasing risk of
death, co-morbidities including poor mental and
physical status, expected noncompliance, orthostat-
ic hypotension plus other factors leading to an in-
creased risk of falls, and polypragmasy [20–22].
Furthermore, older groups more frequently have
contraindications to diagnostic and therapeutic pro-
cedures, as well as difficult access to selected diag-
nostic investigations. Poor elderly representation
in clinical trials may also partly explain what we
found in the studied population of octogenarians, i.e.
suboptimal management from the point of view of
ESC guidelines [23].
Suggestions for future improvement
Adherence of physicians to guidelines of treat-
ment seems to be a strong predictor of fewer car-
diovascular hospitalizations and better outcomes
[24]. These observations may support an urgent
need for the wide introduction of educational pro-
grams on geriatrics for cardiologists [25]. As an
example, participation in OPTIMIZE-HF was asso-
ciated with a high rate of left ventricular assessment
and an increase in evidence-based therapy from the
program’s beginning [26].
We suggest that clinicians treating patients
with HF should indicate the results of the diagnos-
tic procedures (especially ejection fraction or the
presence of diastolic dysfunction) on which the dia-
gnosis was based. They should also document con-
traindications to the use of recommended therapies,
in particular on discharge cards, to bring these to
the attention of other doctors, including general
practitioners.
Taking into account the described age-related
gap in the management of elderly patients, we be-
lieve that HF care may be improved by multidis-
ciplinary management. The involvement of geria-
tricians, other internal medicine specialists (e.g.
pulmonologists), and (in advanced HF) specialists
in palliative medicine may be helpful. Moreover,
those caring for elderly patients, especially those
with poor physical and mental status, should be
comprehensively educated as to HF symptoms and
treatment.
Finally, because the described disparities could
result from the limited amount of evidence-based
data on HF in the elderly, we suggest that elderly
patients should be more adequately represented in
future clinical trials, or that systematic registries
should be carried out and analyzed in these patients.
Conclusions
Despite significant progress in HF manage-
ment, there is still a need for an improvement in
the medical care of very elderly patients. The ma-
jor obstacles seem to be advanced age and the pres-
ence of coexistent pulmonary diseases. Therefore,
the participation of geriatricians and pulmonologists
should be recommended in caring for octogena-
rians with HF.
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